Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie ( (ABBV) ) has issued an update.
On March 4, 2026, AbbVie completed an underwritten public notes offering totaling $8 billion, spanning a mix of senior floating rate notes and unsecured fixed-rate senior notes with maturities ranging from 2028 to 2066. The securities, issued under an existing shelf registration and governed by a long-standing indenture with U.S. Bank Trust Company as trustee, rank equally with AbbVie’s other unsecured, unsubordinated debt and include customary covenants limiting certain liens and corporate restructurings.
The structure of the issuance, including multiple long-dated tranches and flexible optional redemption features such as make-whole call provisions and par calls near maturity, underscores AbbVie’s effort to lock in diversified, long-term funding. This sizable capital raise is poised to bolster the company’s balance sheet and financial flexibility, with implications for ongoing investment in its drug pipeline and potential strategic transactions, while providing fixed-income investors with a spectrum of duration and rate exposure to AbbVie’s credit profile.
The most recent analyst rating on (ABBV) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on AbbVie stock, see the ABBV Stock Forecast page.
Spark’s Take on ABBV Stock
According to Spark, TipRanks’ AI Analyst, ABBV is a Neutral.
The score is primarily held back by balance-sheet risk (high leverage/negative equity) and an expensive P/E multiple despite solid cash generation. Offsetting these are constructive technicals and a notably positive earnings outlook with strong 2026 guidance driven by continued strength in key growth franchises.
To see Spark’s full report on ABBV stock, click here.
More about AbbVie
AbbVie Inc. is a U.S.-based biopharmaceutical company that develops and markets branded prescription drugs across immunology, oncology, neuroscience and other specialty therapeutic areas. The company focuses on large, global markets for chronic and serious conditions, relying heavily on access to capital markets to support research, development and strategic initiatives.
Average Trading Volume: 6,626,155
Technical Sentiment Signal: Buy
Current Market Cap: $413.5B
See more data about ABBV stock on TipRanks’ Stock Analysis page.